

SPH.L

Result of General Meeting

13 January 2011, Godalming, UK: Sinclair Pharma plc (the "Company" or "Sinclair": SPH:L), the international specialty pharma company, is pleased to announce that at a General Meeting of the Company held earlier today, the resolution set out in the notice of general meeting annexed to a circular of the Company dated 22 December 2010, was duly passed without amendment.

The resolution was passed on a show of hands. A breakdown of the proxies lodged prior to the General Meeting in respect of the resolution is summarised below:

	<u>For</u>	<u>Against</u>	<u>Withheld</u>
Resolution 1	100,063,730	30,645,828	1,874,992

Notes:

1. Any proxy arrangements which gave discretion to the Chairman have been included in the "For" totals.
2. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
3. The total number of votes cast by proxy was 132,584,550.
4. The issued share capital of Sinclair as at 11 January 2011 is 231,866,676 ordinary shares.

The results of the proxy votes lodged in advance of the General Meeting will be available on Sinclair's website www.sinclairpharma.com shortly.

In accordance with Sinclair's obligations under Listing Rule 9.6.2, copies of the resolution passed has been submitted to the National Storage Mechanism and will shortly be available for viewing at www.hemscott.com/nsm.do.

For further information please contact:

Sinclair Pharma plc

Chris Spooner, CEO

Alan Olby, CFO

Tel: +44 (0) 1483 410 600

Singer Capital Markets Ltd

Shaun Dobson

Claes Spång

Tel: +44 (0)20 3205 7500

Financial Dynamics

Ben Atwell

Stephanie Cuthbert

Tel: +44 (0)20 7831 3113

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is present in France, Italy, Germany and Spain, and an extensive marketing partner network across selected developed & emerging markets.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.